We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Brendan is a full-time senior editor of financial products and services at ...

Threat actors are evading phishing detection in campaigns targeting Microsoft accounts by abusing the no-code app-building platform Bubble to generate and host malicious web apps. Because the web app ...

The Trump accounts coming this summer let parents jump-start tax-advantaged retirement savings for a child at birth. By the time the kids retire, they could end up with giant retirement accounts. The ...

A major change to federal savings law took effect Jan. 1, 2026, and an estimated one million veterans are newly eligible for a financial tool most have never heard of. The ABLE Age Adjustment Act ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

This is part of a series of CNBC Pro articles designed to help you make the most of your Pro membership and all that CNBC has to offer. Free account benefits With a free account on CNBC.com or the ...

In his State of the Union address, President Donald Trump touted Trump accounts, a type of tax-advantaged investment account for kids, but referred to them as "tax-free." These accounts function like ...

During his State of the Union address Tuesday night, President Donald Trump promoted Trump Accounts — new savings accounts for children, which are set to launch this summer. Subscribe to read this ...

I recently saw a tweet showing how Google has acquired companies over the years and built products around them. Here is the link to the tweet if you want. Now, Google made another announcement: Google ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

Louis Jacobson is the chief correspondent for PolitiFact and a staff writer for the Tampa Bay Times. He has served as deputy editor of Roll Call and as founding editor of its legislative wire service, ...